相关实验视频

Updated: Jun 15, 2026

FIBS-enabled Noninvasive Metabolic Profiling

FIBS-enabled Noninvasive Metabolic Profiling

Published on: February 3, 2014

基于特征的分子网络更新了跨物种的本达的体外代谢表征

Young-Heun Jung¹, Dong-Cheol Lee¹, Bo-Hyun Choi²

¹College of Pharmacy, Yeungnam University, Gyeongsan, Republic of Korea.

Xenobiotica; the fate of foreign compounds in biological systems

|April 25, 2025

概括

基于特征的分子网络识别了fenbendazole (FBZ) 的代谢物,揭示了特定物种的途径. 水解FBZ占主导地位的人体样本,为治疗应用提供了洞察力.

科学领域:

代谢学代谢学代谢学
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

本达 (FBZ) 是一种兽用抗寄生虫药,在人类中显示出新兴的抗癌潜力.
人类对FBZ的代谢途径尚不清楚,这阻碍了其治疗发展.

研究的目的:

使用先进的代谢学来更新班达 (FBZ) 的代谢物表征.
为了在不同物种体内全面描述FBZ代谢物的体外表现.
为了研究FBZ生物转化中的特定物种代谢差异.

主要方法:

利用基于特征的分子网络 (FBMN) 进行代谢学分析.
采用高分辨率液态染色体质谱法 (LC-HRMS) 以数据依赖的MS2获取用于体外代谢物分析.
综合FBMN分析用于代谢物识别和结构特征.

主要成果:

确定了9种FBZ代谢物,包括两种新的硫酸合物 (M2硫酸盐和M7硫酸盐).
观察到的特定物种代谢物概况:大鼠肝脏显微体显示出更高的氧化代谢物 (M1-M4),子肝细胞具有更高的整体代谢物水平.
化FBZ (M5) 是人类肝脏显微体和肝细胞中占主导地位的代谢物,表明具有显著的特定物种酶活性.

结论:

FBMN提供了一种增强的,系统的方法,用于代谢物识别和FBZ的物种间比较.
揭示了关键的代谢差异,支持FBZ生物转化,并为人类治疗用途的安全性和有效性提供了洞察力.

关键词:

基于特征的分子网络.比较的新陈代谢.这种药物是本达 (fenbendazole).肝细胞肝细胞肝细胞肝脏的微粒体肝脏微粒体

更多相关视频

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos

A Manual Small Molecule Screen Approaching High-throughput Using Zebrafish Embryos

Published on: November 8, 2014

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

NMR-Based Activity Assays for Determining Compound Inhibition, IC50 Values, Artifactual Activity, and Whole-Cell Activity of Nucleoside Ribohydrolases

Published on: June 30, 2019

相关概念视频

In vitro Mutagenesis

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.

Anthelminthic Agents

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...